The Application of Adjuvant Radiotherapy in pN1 OSCC Patients Without Adverse Pathologic Features
Oral Diseases · 2025
DOI: 10.1111/odi.15336 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Oral Diseases, 2025. Verfasst von Bo Li und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China. Hauptthemen laut MEDLINE: Mouth Neoplasms, Carcinoma, Squamous Cell. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Capital Medical University, the National Natural Science Foundation of China, the Beijing Science and Technology Commission.
Abstract (Originalsprache)
Purpose
This study aimed to assess the necessity of adjuvant radiotherapy for oral squamous cell carcinoma patients with a pN1 stage and no adverse pathological features. Patients and Methods This was a multicenter cohort study including 231 patients.
Results
Among the enrolled patients, 171 received adjuvant radiotherapy, and 60 did not. According to the Kaplan–Meier survival analysis, there were no significant differences between the two groups in terms of disease‐free survival (59.5% vs. 58.3%, p = 0.938), overall survival (73.1% vs. 75.0%, p = 0.936), and disease‐specific survival (74.9% vs. 76.7%, p = 0.914). In patients with local/regional recurrence after surgery, after‐recurrence survival (34.8% vs. 44.0%, p = 0.197) was not significantly different. Analysis by T stage revealed no significant differences in disease‐free survival (60.9% vs. 75.0%, p = 0.084), overall survival (73.6% vs. 90.6%, p = 0.053) and disease‐specific survival (75.8% vs. 90.6%, p = 0.072) for T1‐2 patients between the radiotherapy and non‐radiotherapy groups. The results revealed statistically significant differences in disease‐free survival (57.9% vs. 39.3%, p = 0.030), overall survival (72.4% vs. 57.1%, p = 0.034) and disease‐specific survival (73.7% vs. 60.7%, p = 0.049) between the two groups.
Conclusions
Adjuvant radiotherapy does not improve the prognosis of T1‐2N1M0 patients without adverse pathological features; however, adjuvant radiotherapy should be recommended for T3‐4aN1M0 patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial-Head and Neck Oncology, Beijing Stomatological Hospital, Capital Medical University, Beijing, China.
- Department of Oral and Maxillofacial and Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Oral and Maxillofacial Surgery, Peking University School and Hospital of Stomatology, Beijing, China.
- Clinical Epidemiology and EBM Unit, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Förderung
- Capital Medical University
- the National Natural Science Foundation of China
- the Beijing Science and Technology Commission
- the Beijing Hospitals Authority Clinical Medicine Development
- the Beijing Nova Program
Zitieren
APA
Li, B., Zhao, Z., Huang, Y., Zhou, H., Zhang, X., Guo, C., Wei, W., Ge, N., Cao, W., & Feng, Z. (2025). The Application of Adjuvant Radiotherapy in pN1 OSCC Patients Without Adverse Pathologic Features. Oral Diseases. https://doi.org/10.1111/odi.15336
Vancouver
Li B, Zhao Z, Huang Y, Zhou H, Zhang X, Guo C, et al. The Application of Adjuvant Radiotherapy in pN1 OSCC Patients Without Adverse Pathologic Features. Oral Diseases. 2025. doi:10.1111/odi.15336
BibTeX
@article{Li2025,
author = {Li, Bo and Zhao, Zhang and Huang, Yu and Zhou, Hanchen and Zhang, Xue and Guo, Chuanbin and Wei, Wei and Ge, Na and Cao, Wei and Feng, Zhien},
title = {The Application of Adjuvant Radiotherapy in pN1 OSCC Patients Without Adverse Pathologic Features},
journal = {Oral Diseases},
year = {2025},
doi = {10.1111/odi.15336}
}
EUVIMED